Qiagen N.v. · NYSE:QGEN
Qiagen — Commerzbank and ODDO BHF German Investment Seminar 2026
15 slides from Qiagen's conference presentation, Jan 13, 2026
Slide 1: Delivering on Commitments and Preparing for Future Growth
DELIVERING ON COMMITMENTS AND PREPARING FOR FUTURE GROWTH Commerzbank and ODDO BHF German Investment Seminar Roland Sackers Chief Financial Officer
Slide 2: Forward Looking and Intended Use Statements
FORWARD LOOKING AND INTENDED USE STATEMENTS Safe Harbor Statement: Certain statements contained in this presentation may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1
Slide 3: Advancing Molecular Research and Diagnostics
ADVANCING MOLECULAR RESEARCH AND DIAGNOSTICS Highly recurring revenues ~5,700 ~90% Consumables and related employees known as QIAGENers revenues ~10% Instruments >500,000 customers worldwide A global company with scale ~52% Balanced customer markets ~$2 Americas ~33% billion Sales1 R&D sales1 EMEA c
Slide 4: Leading from the First Step in Lab Workflows
LEADING FROM THE FIRST STEP IN LAB WORKFLOWS Samples Sample preparation Detection Insights PCR QIAcuity dPCR #2 Any Genomics / NGS Sample #1 biological technologies QIAGEN Digital Insights #1 sample Diagnostic solutions QuantiFERON #1 QIAstat-Dx #2 LIFE SCIENCES CUSTOMERS MOLECULAR DIAGNOSTICS CUSTO
Slide 5: Moving Toward Our 2028 Targets
MOVING TOWARD OUR 2028 TARGETS OUR 2028 On track TARGETS Ongoing focus on growth pillars to At least $2 bn sustain profitable growth net sales CER from pillars in 2028 On track ~7% Set to exceed Net sales CER CAGR (2024-28) Drive efficiency and digitization to At least 250 bps fuel growth investment
Slide 6: 2025: Delivering in a Volatile Environment
2025: DELIVERING IN A VOLATILE ENVIRONMENT Selected milestones Sample technologies LSD growth1 2025 ~5-6% CER core sales outlook4 • First QIAsymphony Connect placements outlook ~$2.38 CER adj. EPS and QIAsprint Connect orders, QIAmini on track outlook • HSD growth in automated consumables3 • Parse:
Slide 7: 2026: Preparing for Future Growth Across Pillars
2026: PREPARING FOR FUTURE GROWTH ACROSS PILLARS Sample tech QuantiFERON QIAcuity QIAstat-Dx QDI Leveraging automation in Enhancing workflow and Driving growth and preparing Broadening syndromic Capitalizing on top market high-value areas customer retention new generation testing panels position wit
Slide 8: Launching a New Generation of Automation
LAUNCHING A NEW GENERATION OF AUTOMATION QIAcuity Sample technologies On On On NEW track track track + Hamilton® Microlab QIAmini QIAsprint Connect Launch 2026 QIAsymphony Connect STAR Launch February 2026 NEW Full IVDR launch mid-2026 Launch Fall 2026 Launch 2026 • Partnering with Hamilton® on • Hi
Slide 9: 2026: Driving Growth Through Portfolio Expansion
2026: DRIVING GROWTH THROUGH PORTFOLIO EXPANSION Sample tech QuantiFERON QIAcuity QIAstat-Dx NEW QIAsprint Connect Advancing workflow Gene expression QIAstat-Dx Rise Introducing broad menu for New chemistry and workflow New high-multiplex chemistry Adding three new GI panels >30 sample types automat
Slide 10: Parse: Breaking Single-Cell Limits
PARSE: BREAKING SINGLE-CELL LIMITS SCALABLE HIGH QUALITY AI READY Designed for next-gen biology Validated for consistent performance Built for translational reality >1,000x higher single-cell scale Data quality determines value at AI models need biologically diverse reported over the last 10 years s
Slide 11: Genoox: The AI-Powered Software Platform
GENOOX: THE AI-POWERED SOFTWARE PLATFORM SPEED ACCURACY CONFIDENCE Optimized for clinical turnaround AI workflows augmented by scientists Proven across >5.5 million reports Continuous feedback through users AI outputs validated by expert review Gold-standard knowledge databases HOW WE WIN HOW WE WIN
Slide 12: Leveraging AI to Enhance Growth and Efficiency
LEVERAGING AI TO ENHANCE GROWTH AND EFFICIENCY Advancing AI across QDI Driving AI and digitization across QIAGEN Progressing on AI roadmap in 2026 Moving from individual projects to integrated programs QDI R&D Commercial Sales Customer service ~40% 4 ~65% ~50% R&D leveraging AI for coding New AI-enh
Slide 13: Allocating Capital for Growth and Highest Returns
ALLOCATING CAPITAL FOR GROWTH AND HIGHEST RETURNS Investing with clear return targets to drive shareholder value Investing to support future growth Increasing returns to shareholders Organic investments Targeted bolt-on M&A Share repurchase programs Annual dividend Optimize R&D and CAPEX Accretive t
Slide 14: 2026 Outlook: Positioned for Growth
2026 OUTLOOK: POSITIONED FOR GROWTH Drive solid sales growth through pillars Our 2028 targets Launch new platforms and expand menu to drive recurring revenues ~7% Net sales CER CAGR Leverage portfolio in high-value areas (2024-28) Increase focus on applications offering dynamic growth ≥31% Deliver v
Slide 15: Delivering on Commitments and Preparing for Future Growth
DELIVERING ON COMMITMENTS AND PREPARING FOR FUTURE GROWTH Commerzbank and ODDO BHF German Investment Seminar
Qiagen — Commerzbank and ODDO BHF German Investment Seminar 2026 on 6ix